Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites


Creative Commons License

Gumusay O., Benekli M., EKİNCİ Ö., Baykara M., ÖZET A., Coskun U., ...More

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.45, no.5, pp.416-421, 2015 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 5
  • Publication Date: 2015
  • Doi Number: 10.1093/jjco/hyv020
  • Journal Name: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.416-421
  • Keywords: HER2, gastric cancer, discordance, IHC, SISH, HETEROGENEOUS AMPLIFICATION, CLINICAL-SIGNIFICANCE, GENE AMPLIFICATION, SCORING SYSTEM, BREAST-CANCER, HYBRIDIZATION, CARCINOMA, EXPRESSION, ERBB2, IMMUNOHISTOCHEMISTRY

Abstract

Objective: Determination of human epidermal growth factor receptor-2 status in advanced gastric cancer is important in clinical decision making. In the trastuzumab for GC trial, trastuzumab-based therapy demonstrated a significant overall survival benefit in patients with human epidermal growth factor receptor-2-positive advanced gastric cancer. Human epidermal growth factor receptor-2 discordance in gastric cancer primary and its metastases has been long debated. The aim of the study was to evaluate the rate of human epidermal growth factor receptor-2 discordance and its effect on treatment decisions in advanced gastric cancer.